par Lenz, Oliver;Vijgen, Leen;Berke, Jan Martin;Cummings, Maxwell D;Fevery, Bart;Peeters, Monika P.;De Smedt, Goedele;Moreno, Christophe ;Picchio, Gaston
Référence Journal of hepatology, 58, 3, page (445-451)
Publication Publié, 2013-03
Référence Journal of hepatology, 58, 3, page (445-451)
Publication Publié, 2013-03
Article révisé par les pairs
Résumé : | TMC435 is a potent, once-daily, investigational hepatitis C virus (HCV) NS3/4A protease inhibitor in phase III clinical development. In the phase II trial TMC435-C202 (NCT00812331), TMC435 displayed potent activity in genotype 4, 5 and 6 patients and in 3/6 genotype 2 patients, whereas no activity was observed with genotype 3. |